Researchers have found that new sickle cell disease gene therapies depend on choosing the right laboratory mice.
Scientists from St. Jude Children’s Research Hospital, US, have been investigating a promising new sickle cell treatment by editing genes to switch on the production of healthy, fetal hemoglobin in adult red blood cells.